Avalyn Pharma Inc.
Public company- Headquarters
- BOSTON, Massachusetts
- Ticker
- AVLN
- CIK
- 0001540171
WARN notices since 2024
0
None on record
Workers affected since 2024
0
Across 0 notices
Executive changes, last 12 months
1
1 appointment, 0 departures
Last event
Sep 16, 2026
Executive appointmentClass II director appointed: Robert Meyer, M.D.
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Class II directorRobert Meyer, M.D. | Sep 16, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ENANTA PHARMACEUTICALS INC
CEO departs: Jay R. Luly, Ph.D.
- VERTEX PHARMACEUTICALS INC / MA
new member of the board of directors appointed: Daniel Brennan
- Ernexa Therapeutics Inc.
member of the Board appointed: Robert J. Spiegel, M.D.
- BRISTOL MYERS SQUIBB CO
WARN notice: Princeton, NJ
- Executive appointment
Class II director appointed: Robert Meyer, M.D.
Robert Meyer, M.D. was named Class II director of Avalyn Pharma Inc., effective September 15, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 16, 2026Role: Class II director
Only one public record so far. We add events as soon as a new filing lands; watch Avalyn Pharma Inc. to get them in your digest.
Last verified Nov 8, 2026